Nicox SA (ALCOX)

Currency in EUR
0.586
+0.064(+12.26%)
Real-time Data·
ALCOX Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Unusual trading volume
Trading near 52-week High
ALCOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.5300.600
52 wk Range
0.1400.600
Key Statistics
Prev. Close
0.522
Open
0.56
Day's Range
0.53-0.6
52 wk Range
0.14-0.6
Volume
2.56M
Average Volume (3m)
581.14K
1-Year Change
208.15%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALCOX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.000
Upside
+70.65%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Nicox SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Nicox SA Company Profile

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.

Employees
28
Market
France

Compare ALCOX to Peers and Sector

Metrics to compare
ALCOX
Peers
Sector
Relationship
P/E Ratio
-−2.2x−0.5x
PEG Ratio
-0.020.00
Price/Book
-1.6x2.6x
Price / LTM Sales
-3.9x3.3x
Upside (Analyst Target)
342.5%134.6%43.5%
Fair Value Upside
Unlock14.9%6.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.000
(+70.65% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-0.06 / -0.06
Revenue / Forecast
-- / 400.00K
EPS Revisions
Last 90 days

ALCOX Income Statement

People Also Watch

3.13
ETL
-4.73%
253.60
ESLX
+1.72%
11.02
AL2SI
-2.13%
59.50
ABVX
-2.94%
120.40
EXA
-1.31%

FAQ

What Stock Exchange Does Nicox Trade On?

Nicox is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for Nicox?

The stock symbol for Nicox is "ALCOX."

What Is the Nicox Market Cap?

As of today, Nicox market cap is 42.31M.

What Is Nicox's Earnings Per Share (TTM)?

The Nicox EPS (TTM) is -0.37.

When Is the Next Nicox Earnings Date?

Nicox will release its next earnings report on 14 Oct 2025.

From a Technical Analysis Perspective, Is ALCOX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Nicox Stock Split?

Nicox has split 4 times.

How Many Employees Does Nicox Have?

Nicox has 28 employees.

What is the current trading status of Nicox (ALCOX)?

As of 07 Aug 2025, Nicox (ALCOX) is trading at a price of 0.59, with a previous close of 0.52. The stock has fluctuated within a day range of 0.53 to 0.60, while its 52-week range spans from 0.14 to 0.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.